Trevi Therapeutics, Inc.(TRVI)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Trevi Therapeutics remains a high-risk, clinical-stage entity characterized by a complete lack of commercial revenue and persistent quarterly operating losses that reached $14.9 million in 2026Q1.
• The company's reliance on R&D-heavy spending, which consistently consumes millions in quarterly capital, necessitates frequent external financing that threatens to dilute existing shareholders.
• Investors should monitor the firm's ability to reach critical clinical milestones before its $19.4 million cash balance is fully exhausted by ongoing operational burn.